Free tool
Cell therapy stocks
We cover 5 companies grouped under the Cell therapy theme. The median market value in the group is $2.25B. Across the group, the median move over the past trading day is −2.04%. Price change over the past year runs from −23.9% to +147.6% across the middle 80 percent of the group, with a median of +4.5%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $20.68 | +8.61% | −3.86% | −40.44% |
| IOVA | Iovance Biotherapeutics, Inc. | $8.08 | +71.91% | +220.63% | +233.88% |
| MSB.AX | Mesoblast Limited | 2.45 AUD | +19.85% | −11.73% | +1.03% |
| MESO | Mesoblast Limited | $16.84 | +16.54% | −7.27% | +4.47% |
| VCEL | Vericel Corporation | $42.44 | −9.14% | +19.18% | +18.25% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.